CreateAI, a Leader in Applied AI Technology, Launches Animon.ai Studio Version for Creators to Make Their Own Anime Series
TOKYO, July 29, 2025 /PRNewswire/ -- CreateAI Holdings ("CreateAI" or the "Company") (OTC: TSPH), a leader in applied artificial intelligence technology, today announced the launch of the Studio Version of Animon.ai, the world's first anime-specific AI video generation platform, just three months after its initial debut. Studio Version is a major upgrade that enables individual creators to produce professional-grade anime series with unprecedented efficiency and creative control.
With powerful new tools and features, the Studio Version fully supports every stage of the anime series workflow, focusing on three core aspects of production: high-quality image generation, keyframe consistency, and final shot output—each now enhanced to professional standards to help creators boost productivity, overcome bottlenecks, and unleash creativity.
Start with Stunning Visuals: Generate High-Quality Anime Frames
The Studio Version offers a dedicated image generation model, Aniframe, supporting 2K HD quality, excelling in panoramic, close-up, and detailed scenes. These cover diverse anime styles such as classic Japanese, picture book, line art, pixel, illustration, blind box, ink wash, watercolor, poster design, furry, and engraving, offering the ability to generate up to eight images simultaneously fulfilling a host of project needs.
Build Narrative Flow: Maintain Character and Scene Consistency with Image Editing Tools
New image-to-image and editing features (e.g., background replacement, pose adjustment, style switching, partial recoloring, and element addition/removal) support multiple aspect ratios and return up to four images for selection, giving creators greater freedom and control—solving the long-standing challenge of maintaining character consistency across frames.
Bring it to Life: Transform Keyframes into Smooth, Cinematic Video Sequences
Enhanced image-to-video capabilities with the Anicut model series, featuring in-between (first/last frame) generation at 16fps; sharp camera movement control and accurate scene transition editing; and, super-resolution upgrading from 480p / 16fps to 1080p / 24fps. Up to eight videos can be generated simultaneously, significantly improving production efficiency.
Collaborate and Scale: Studio-Level Tools for Teams and Professionals
Features an immersive collaboration interface, priority computing access, and 24/7 technical and engineering support to streamline team collaboration and ensure seamless creative processes.
"We're excited to release Animon Studio Version for creators to make their own anime series," said Cheng Lu, President and CEO of CreateAI. "Animon's goal is to make the most professional creation tools accessible to all, helping creators overcome resource and efficiency barriers to bring their animation ideas to life."
Yuji Maruyama, Animon.ai Product Lead, added, "Every Studio Version feature addresses real pain points in anime production. From 2K HD images to precise first/last frame control, we've optimized the workflow allowing creators to rapidly generate high-quality assets and videos to make their own anime series."
Animon.ai is building the world's first IDE (Integrated Development Environment) for anime series production. Offering unlimited generation from the beginning, the company has steadily evolved its tools and workflows to support creators at every step. The Studio Version is a major milestone in that direction.
Animon.ai Studio Version is now live and available at 49.9 $/month. Creators can try it with a three-day membership for just $0.99. Upcoming features include initial frame presets, scene expansion, and integrated soundtrack tools—bringing creators even closer to a seamless, end-to-end anime production experience.
Animon Media Contact:
pr@animon.ai
About CreateAI
CreateAI is a global applied artificial intelligence company with offices in the US, China, and Japan. The Company is developing leading AI technology for a number of end-use applications and pioneering the future of digital entertainment content production, seamlessly blending cutting-edge generative AI technology with the creativity of world-class talent. Our mission is to redefine the boundaries of what's possible in digital storytelling by developing immersive, captivating, and visually stunning experiences that resonate with audiences on a global scale.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
6 hours ago
- Korea Herald
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, unveiled two new technologies at ADLM 2025 in Chicago (July 29–31) designed to advance laboratory automation and data-driven infectious disease monitoring. The company introduced CURECA™, world's first fully unattended PCR automation system, and STAgora™, a real-time data analytics platform intended to support earlier detection and precision care. Chairman Highlights Next Step in Molecular Diagnostics "With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." Today, most molecular testing systems remain only partially automated, dependent on skilled personnel for repetitive manual steps and fixed workflows that limit efficiency and scalability. CURECA™ Breaks the Limits of Automation to Reshape Global Diagnostics CURECA™ is the first system in the diagnostics industry designed to fully automate every step of PCR testing, including the traditionally manual pre-treatment stage. Seegene notes that achieving true full automation in diagnostics requires three key conditions: operation without highly trained professionals, continuous 24-hour processing, and uninterrupted specimen input. CURECA™ is designed to meet all three. Its dedicated module, CURECA™ Prep, processes a wide range of specimen types such as urine, blood, sputum, and stool, addressing one of the most persistent barriers to automation. With the module handling diverse specimen pre-treatment, the full CURECA™ system completes the entire PCR workflow from sample loading through nucleic acid extraction, amplification, and result analysis without manual intervention. The system is engineered for continuous 24-hour operation, aiming to minimize human error, improve workflow efficiency, and allow laboratories to allocate skilled staff to higher-value activities. Full automation has long been a challenge in diagnostics due to specimen variability and the reliance on trained personnel for repetitive pre-processing tasks. CURECA™ is intended to help laboratories overcome these constraints by providing a scalable and adaptable system that can be configured to fit different lab sizes and workflows. CURECA™ Prep could also potentially extend to other testing fields, such as clinical chemistry and immunodiagnostics, as Seegene continues to explore broader automation solutions. STAgora™ Transforms Diagnostic Data into Real-Time Clinical Intelligence STAgora™ is Seegene's latest platform, designed to collect and analyze PCR testing data in real time, providing laboratories with broader context to inform diagnostic workflows. The platform includes more than 40 analytical tools, offering functions such as infection trend tracking, hospital-level positivity monitoring, and multi-pathogen co-infection pattern analysis. Rather than serving as a simple data repository, STAgora™ is built as an integrated platform intended to help laboratories derive meaningful, aggregated insights from testing data. Today, individual test results often provide limited information without broader reference points. STAgora™ is designed to address this by enabling hospitals to build their own statistical datasets and compare aggregated data across institutions, helping them detect infection patterns faster and support more informed decision-making. The data shared through the platform is de-identified and formatted according to each institution's requirements, supporting secure, real-time exchange at local, national, or global levels. Advancing Toward a World Free from All Diseases Dr. Chun reiterated Seegene's long-term vision of building "a world free from diseases" noting that the introduction of CURECA™ and STAgora™ completes the company's five core technology pillars. These include Seegene's proprietary PCR technology, the SGDDS (Seegene Digitalized Development System) for automated assay development, its global Technology-Sharing Initiative, and now the addition of fully automated PCR testing and real-time data analytics capabilities. Industry experts at ADLM 2025 expressed strong interest in Seegene's new technologies. Jamel Giuma, President and CEO of Miami based laboratory IT consulting firm JTG Consulting Group, said, "I've attended many ADLM conferences over the years, and CURECA™ is one of the most innovative solutions I have seen so far. I believe it has the potential to simplify laboratory workflows, reduce the burden on lab personnel, and greatly enhance overall operational efficiency." "With CURECA™ and STAgora™, we're addressing long-standing barriers in molecular diagnostics," Dr. Chun added. "Just as smartphones and electric vehicles transformed their industries, we believe these technologies will redefine what is possible in diagnostic testing, helping laboratories worldwide achieve true automation, unlock the value of diagnostic data, and ultimately contribute to building a world free from diseases." Disclaimer CURECA™ and STAgora™ demonstrated at ADLM 2025 are pre-commercial technologies under development, not commercially available, and are not currently cleared for clinical diagnostic use in any jurisdiction.
Korea Herald
8 hours ago
- Korea Herald
First-of-Its-Kind Japan Preschool Exchange Lets Global Families Experience Real Japanese School Life -- With a Little Help from Peppa Pig
TOKYO, Aug. 5, 2025 /PRNewswire/ -- Japan Preschool Exchange (JPE), a cultural exchange program, invites global families to experience daily life at real Japanese preschools—from snowy play to rice harvesting in nature-rich communities. Families can join for 1 to 3 weeks with no Japanese knowledge required. JPE partners with over 30 trusted preschools nationwide, supporting local sustainability and offering unforgettable experiences. Since launching in 2021, JPE has welcomed over 1,000 participants, with 95% saying they would return. The program has earned multiple government awards. Founded by CEO Masaya Yamamoto after staying with his daughter at a rural preschool in Hokkaido, JPE promotes cross-cultural learning and nature-connected childhoods. To reach more families worldwide, JPE is launching an official promotion with PEPPA PIG, Hasbro's beloved preschool brand. Families who register for the experience during the campaign (from 1st August, 2025 to 30th June, 2026) will receive a PEPPA PIG Welcome Digital Guide, which includes a variety of activity sheets for kids. Embracing Peppa Pig's ethos of inspiring kids' confidence, the campaign invites families to jump in together and savor the precious early childhood years through real-life adventures in Japanese preschools. JPE also welcomes school groups for educational trips, joining a global network of cultural exchange communities. About KitchHike KitchHike is a Japan-based brand studio and platform empowering rural regions through place-based innovation. As population decline becomes a global reality, KitchHike sees Japan's rural communities not as outliers, but as prototypes of the planet's future. It leads projects driven by the mission: "Amplify local potential. Shape a sustainable planet." About Hasbro Hasbro is a leading games, IP, and toy company whose mission is to create joy and community through the magic of play. Hasbro reaches over 500 million kids, families, and fans globally through physical and digital games, video games, toys, licensed consumer products, location-based entertainment, film, TV, and more. About PEPPA PIG PEPPA PIG is a British preschool animated television series that has aired for over 20 years, across 10 seasons in over 180 territories. The series follows Peppa, a cheeky little piggy who lives with her family - younger brother George, baby sister Evie, Mummy Pig and Daddy Pig - as well as her diverse community of friends.
Korea Herald
9 hours ago
- Korea Herald
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
• Successful validation of payloaded anti-colibactin toxin phage using IMPA ™ technology • Demonstrated ' Dual-target Therapeutic Strategy ' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular concern. This bacterium produces a toxic substance in the intestine that causes DNA damage (ICLs, Interstrand Cross-Links), which leads to DSBs (Double Strand Breaks), and has been shown in numerous studies, including Nature (2023), to increase the risk of colorectal cancer over time. Amid this situation, as an innovative bacteriophage technology development company, iNtRON Bio proposes a new possibility for microbiome-based anticancer drugs in treating colorectal cancer—considered a hard-to-treat disease—by applying our phage engineering technology called IMPA™. iNtRON Bio has been developing PHAGERIA Ⓡ, an immunotherapeutic targeting gut bacteria, and through the IMPA™ phage engineering technology developed in-house, iNtRON Bio has secured a new drug candidate payloaded with a substance that effectively eliminates colibactin ,a major causative agent of colorectal cancer and have filed a related US patent application. The phage engineering technology IMPA™ (Intelligent Modular Phage Assembly) was formerly known as the "robot bacteriophage." With the recent US patent application, it was named to clearly reflect the function as a technology for engineering modular phages (mock-up phages) that can carry therapeutic payloads. This achievement is the result of combining transposon mutagenesis, CRISPR/Cas-based forward/reverse genetics, and AI-driven analysis capabilities to explore the possibility of delivering various functional payloads. In particular, it is highly significant that iNtRON Bio successfully loaded a payload targeting colibactin ,deeply involved in colorectal cancer, onto the surface of the phage and, for the first time globally, confirmed its effectiveness. In other words, iNtRON Bio has demonstrated a dual-targeting therapeutic approach that not only eliminates pks+ E. coli, which is a main cause of colorectal cancer, but also neutralizes the toxin secreted by this bacterium. This includes verifying colibactin's role in cancer development, confirming the suppressive effect of modular phage on colorectal cancer, and proving the phage's colibactin-degrading ability—resulting in successful proof-of-concept studies and related patent acquisition. Simply put, the core of this development is that a colibactin-degrading protein was applied as a payload on the phage's protein shell, known as the capsid. Like a precision-guided missile with a warhead, the engineered phage specifically infects pks+ E. coli, kills the bacteria, and at the same time removes the colibactin toxin already secreted by the bacterium using the enzyme carried in the capsid—offering a dual therapeutic effect. Recently, the field of bacteriophage engineering is gaining attention globally. IMPA™ technology is not only a unique platform technology differentiated from other companies, but also serves as strong evidence that it can function as an actual drug delivery platform beyond simple research use. It is encouraging that iNtRON Bio's research has overcome key limitations of conventional phage-based technologies, such as decreased payload activity and phage structural instability when therapeutic substances are loaded. By confirming that the payload retains its original function, iNtRON Bio has demonstrated that it has successfully overcome high technical hurdles. The engineered phages are not merely for research purposes but were selected and validated through multiple tests with real-world and human applications in mind. iNtRON Bio has applied an advanced AI-driven optimization platform technology, refined it with great care, and plan to extend its application to other development fields for ongoing innovation. This achievement is not only a remarkable advancement in phage engineering technology but will also become a driving force for discovering innovative microbiome drug candidates through integration with other phage-based platform technologies of iNtRON Bio. It will proceed smoothly with preclinical studies including proof-of-concept (PoC) testing for combination effects with existing colorectal cancer therapies. In addition, IMPA™ phage engineering technology will be applied more broadly to ADC drug development, anti-cancer agent, and vaccines, as iNtRON Bio continues to strengthen our global technological competitiveness in these fields.
